Blood components: current challenges.
Labile blood products are still here to stay for quite a long time. All European surveys come in agreement to reveal that indications, extremely heterogeneous from one country to another, are not fully under control. Both the EuroNet-TMS network and Euro'SAT congresses aim at improving the use of such products within an evidence-based medicine perspective.